National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Daclatasvir (Daklinza®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4). 

Rapid Review

Commenced Completed Outcome
05/08/2014 12/09/2014 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
01/12/2014  29/05/2015 Reimbursement recommended for certain subgroups

Summary